Nautilus Biotechnolgy, Inc. (NASDAQ: NAUT) is a Healthcare company (Biotechnology) with a market capitalization of $301M. The Maz Rating grades it against the other companies in its sector.
Nautilus Biotechnolgy, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $2.36, Nautilus Biotechnolgy, Inc. trades at 715.0x sales and 2.6x book value. Over the last twelve months it generated about $420437 of revenue and a net loss of $58M. It runs a gross margin of -362.5%, an operating margin of -15105.7% and a net margin of -13816.7%. It shows return on equity of -42.7%, return on invested capital of -44.7% and a free cash flow yield of -18.3%. On the balance sheet: a debt-to-equity ratio of 0.23 and a current ratio of 9.25. Over the past 52 weeks the share price ranged from $0.84 to $4.31, with a beta of 0.87.
Nautilus Biotechnolgy, Inc. does not currently pay a dividend.
5 Wall Street analyst ratings cover the stock: 3 Buy, 1 Hold and 1 Sell, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.